Clinical-stage drug development company Invion Limited (ASX:IVX) is pleased to advise that CEO Dr William Garner will be presenting at the highly anticipated Australasian Life Science Investment Summit (ALSIS), Friday 2 November 2012, part of the AusBiotech 2012 national conference.
The invitation-only event showcases Australia’s most promising biotechnology companies who are actively seeking capital or partnership opportunities, and attracts an audience of national and international investors, including angel investors, venture capitalists, fund managers, investment bankers and representatives from superannuation funds.
Presenting companies briefly pitch the company’s value proposition to a large audience, and then build on the engagement with networking opportunities and meetings facilitated by the Summit. Independent research from ALSIS 2011 showed that at the end of the Summit A$228 million worth of deals were in discussion.
“This is a great opportunity to showcase Invion’s clinical programs and investment potential, and we are very pleased to take up the chance to meet new investors and reconnect with existing shareholders. It is a highlight of our recent investor outreach program, which has expanded our network in both Australia and Asia,” said Dr Garner.
Dr Garner has just returned from investor meetings in Asia, and is in Australia for ALSIS, as well as further showcase meetings scheduled for Melbourne, Sydney and Brisbane. The company’s AGM is being held at 10.30am, Thursday 8 November.